MED

EQS-News: MEDICLIN achieves consolidated Group sales of EUR 730.1 million in 2023 - outlook for 2024 is positive

Retrieved on: 
Wednesday, April 10, 2024
EUR, WKN, CFO, Coronavirus, Sale, Bad, MED, Ticker, Rehabilitation, Lithium

At Group level, sales of EUR 730.1 million were achieved, an increase of 3.6% compared to 2022.

Key Points: 
  • At Group level, sales of EUR 730.1 million were achieved, an increase of 3.6% compared to 2022.
  • At EUR 12.7 million, the Group operating result was EUR 6.8 million below the previous year's figure (2022: EUR 19.5 million) due to a one-off effect.
  • Sales include services from the protective shield totalling EUR 7.4 million, which is less than in 2022 (EUR 11.7 million).
  • Sales in the acute segment totalled EUR 254.0 million, an increase of EUR 1.3 million or 0.5% compared to the previous year.

EQS-News: MEDICLIN invites you to the virtual press conference on the financial statements for the year 2023

Retrieved on: 
Wednesday, April 10, 2024
Webcast, Bank statement, Ticker, Q&A, MED, WKN

MEDICLIN (Ticker: MED; WKN 659 510) invites you to the virtual press conference on the financial statements for the year 2023.

Key Points: 
  • MEDICLIN (Ticker: MED; WKN 659 510) invites you to the virtual press conference on the financial statements for the year 2023.
  • The event will take place on
    The Management Board of MEDICLIN will report on the 2023 financial year, current developments at MEDICLIN and the outlook for 2024 in a webcast.
  • To participate in the press conference, please register at the following link:
    You will then receive the link to the webcast and the dial-in details for the telephone connection.
  • The replay of the webcast (without the Q&A session) will be available on the MEDICLIN website soon after the press conference.

Urethral Dilator Market to reach $390.1 million by 2031, at a CAGR of 6.1%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Hospital, Urination, Friction, Growth, Prevalence, Risk, Trauma, Research, Dilator, Cook Group, Urethral stricture, Urethra, MED, Medical imaging

Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.

Key Points: 
  • Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.
  • The market for urethral dilators is witnessing significant growth due to the rising prevalence of urethral strictures.
  • This has led to an increased demand for urethral dilators, which are used to widen the urethra and alleviate the symptoms of urethral strictures.
  • The growing adoption of minimally invasive procedures, such as urethral dilatation, is also contributing to the market opportunity for urethral dilators.

Urethral Dilator Market to reach $390.1 million by 2031, at a CAGR of 6.1%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Hospital, Urination, Friction, Growth, Prevalence, Risk, Trauma, Research, Dilator, Cook Group, Urethral stricture, Urethra, MED, Medical imaging

Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.

Key Points: 
  • Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.
  • The market for urethral dilators is witnessing significant growth due to the rising prevalence of urethral strictures.
  • This has led to an increased demand for urethral dilators, which are used to widen the urethra and alleviate the symptoms of urethral strictures.
  • The growing adoption of minimally invasive procedures, such as urethral dilatation, is also contributing to the market opportunity for urethral dilators.

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

Retrieved on: 
Thursday, April 4, 2024
Health, Oncology, Cardiology, Medical Devices, Radio, MED, Dialysis, Pulmonary embolism, Growth, Patient, News, Nanoknife, Cancer, Public expenditure, Table, APEX, Quality of life, PICC, Radiofrequency ablation, IP, GAAP, Patent, Starburst, FDA, Medical laboratory scientist, Pharmaceutical industry

Net sales for the third quarter of fiscal year 2024 were $66.0 million, an increase of 8.0% compared to the prior-year quarter.

Key Points: 
  • Net sales for the third quarter of fiscal year 2024 were $66.0 million, an increase of 8.0% compared to the prior-year quarter.
  • U.S. net sales in the third quarter of fiscal 2024 were $55.8 million, an increase of 5.9% from sales of $52.7 million a year ago.
  • GAAP reported gross margin was 47.7%, a decrease of 250 basis points compared to the third quarter of fiscal 2023.
  • On a pro forma basis, gross margin for the third quarter of fiscal 2024 was 51.1%, a decline of 290 basis points from the third quarter of fiscal 2023.

Veristat Joins the Alliance for Regenerative Medicine (ARM) to Help Address Critical Issues Impacting the Advanced Therapy Sector

Retrieved on: 
Wednesday, April 3, 2024
Stem Cells, Consulting, Pharmaceutical, Oncology, Professional Services, Biometrics, General Health, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Health, Research, MED, Member, Regenerative medicine, Patient, ARM, Pharmaceutical industry

The announcement falls the week before members of Veristat’s Executive team are attending ARM’s Cell & Gene Meeting on the Med (#MeetingOnTheMed) being held in Rome, Italy.

Key Points: 
  • The announcement falls the week before members of Veristat’s Executive team are attending ARM’s Cell & Gene Meeting on the Med (#MeetingOnTheMed) being held in Rome, Italy.
  • “Advanced therapies have proven themselves as holding numerous benefits for patients struggling with rare and ultra-rare diseases, areas that account for 35% of our work,” stated Patrick Flanagan, Chief Executive Officer of Veristat.
  • “Veristat is proud to have supported the development of the first gene therapy approved in Europe.
  • ARM’s mission centers on enabling the development of advanced therapies and the modernization of healthcare systems so that patients benefit from durable, potentially curative treatments.

Vesigen to Present at the 2024 Cell and Gene Meeting on the Med

Retrieved on: 
Wednesday, April 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, MED, Tissue engineering, Cell, Regenerative medicine, RNA, Gene editing, Therapy

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.

Key Points: 
  • Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.
  • Virtual attendance is available which includes a livestream of Vesigen’s presentation and the ability to view all conference sessions on-demand.
  • Visit https://meetingonthemed.com/ for full information including registration.
  • Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Med is a three-day conference featuring more than 60 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.

Kytopen Announces Launch of Technology Access Program Supported by an Expanded Applications Team

Retrieved on: 
Tuesday, March 26, 2024
MED, Seminal vesicles, Research, Business development, TAP, MSC, CRISPR, Safety, Therapy

and DENVER, March 26, 2024 /PRNewswire/ -- Kytopen Corp., a leader in the development of manufacturing platforms and workflows for advanced therapeutic medicines, announces the launch of the Flowfect® Technology Access Program ("TAP") for early access to partners.

Key Points: 
  • and DENVER, March 26, 2024 /PRNewswire/ -- Kytopen Corp., a leader in the development of manufacturing platforms and workflows for advanced therapeutic medicines, announces the launch of the Flowfect® Technology Access Program ("TAP") for early access to partners.
  • "The Kytopen team is excited and proud to launch our Technology Access Program.
  • Earlier this year, Kytopen significantly expanded its process development and applications team with the hiring of researchers formerly from Artisan Bio, a developer of novel CRISPR editing systems and cell therapies, to support the incoming Technology Access Program partners and development of templated manufacturing processes for emerging non-viral applications.
  • Please reach out to [email protected] to request more information on the Flowfect® Technology Access Program.

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Retrieved on: 
Thursday, February 22, 2024
Epilepsy, Pharmacology, DSM-IV codes, Research, GABAA, Drug resistance, 300X, Dizziness, Drug development, PAM, Volunteering, GAERS, Risk, Generalized tonic–clonic seizure, Deficit spending, Rat, Therapy, Ataxia, Memory, MED, Human, Cognition, Patient, Somnolence, Addiction, Partnership, Pharmaceutical industry

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.

Key Points: 
  • MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.
  • The publication describes the extent of anti-seizure activity of BAER-101 in the GAERS model, a widely used and translationally relevant animal model.
  • The study demonstrated full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg.
  • “The preclinical data published in Drug Development Research demonstrate BAER-101’s ability to fully suppress seizures in the GAERS model, a translational animal model for anti-seizure drug development with a documented high predictability of response in humans.

Four Seasons Resort Peninsula Papagayo Celebrates Eighth Consecutive Forbes Travel Guide Five Stars honors

Retrieved on: 
Wednesday, February 7, 2024
Pura, Multimedia, Season, Associate, Heart, Pollyanna, Restaurant, Accor, Relaxation, Forbes Travel Guide, MED, Pura Vida, Rejuvenation, Five star, Hotel

GUANACASTE, Costa Rica, Feb. 7, 2024 /PRNewswire/ -- Four Seasons Resort Peninsula Papagayo proudly announces its eighth consecutive Forbes Travel Guide Five Stars award, reaffirming its commitment to providing unparalleled luxury and service in the hospitality industry.

Key Points: 
  • GUANACASTE, Costa Rica, Feb. 7, 2024 /PRNewswire/ -- Four Seasons Resort Peninsula Papagayo proudly announces its eighth consecutive Forbes Travel Guide Five Stars award, reaffirming its commitment to providing unparalleled luxury and service in the hospitality industry.
  • "Receiving the Forbes Travel Guide Five Stars for the eighth consecutive year is a testament to our team's dedication to providing exceptional experiences.
  • Since its opening, Four Seasons Resort Peninsula Papagayo has consistently set the benchmark for luxury and service in the region.
  • Four Seasons Resort Peninsula Papagayo is honored to be part of this elite group, and the continuous acknowledgment by Forbes Travel Guide is a testament to the resort's commitment to excellence.